KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Arbutus Biopharma (ABUS) Tax Provisions (2016 - 2022)

Arbutus Biopharma (ABUS) has disclosed Tax Provisions for 6 consecutive years, with $4.4 million as the latest value for Q1 2022.

  • Quarterly Tax Provisions changed N/A to $4.4 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $4.4 million through Dec 2022, changed N/A year-over-year, with the annual reading at $4.4 million for FY2022, N/A changed from the prior year.
  • Tax Provisions hit $4.4 million in Q1 2022 for Arbutus Biopharma, up from -$12.7 million in the prior quarter.
  • In the past five years, Tax Provisions ranged from a high of $4.4 million in Q1 2022 to a low of -$12.7 million in Q3 2019.
  • Historically, Tax Provisions has averaged -$4.2 million across 3 years, with a median of -$4.3 million in 2018.
  • Biggest YoY gain for Tax Provisions was 195.56% in 2019; the steepest drop was 195.56% in 2019.
  • Year by year, Tax Provisions stood at -$4.3 million in 2018, then crashed by 195.56% to -$12.7 million in 2019, then soared by 135.11% to $4.4 million in 2022.
  • Business Quant data shows Tax Provisions for ABUS at $4.4 million in Q1 2022, -$12.7 million in Q3 2019, and -$4.3 million in Q3 2018.